Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qi Zhi Wei Tong granules (also known as Qi-Zhi-Wei-Tong Keli) is a traditional Chinese patent medicine approved by the National Medical Products Administration (NMPA) of China for the treatment of functional dyspepsia and gastrointestinal motility and sensory disorders. It is a multi-herb formulation composed of six traditional Chinese medicinal herbs: Radix Bupleuri (Chaihu), Rhizoma Corydalis (Yanhusuo), Fructus Aurantii (Zhike), Rhizoma Cyperi (Xiangfu), Radix Paeoniae Alba (Baishao), and Radix Glycyrrhizae (Gancao). Qi Zhi Wei Tong granules work by soothing the liver, regulating Qi, and relieving stomach pain. Preclinical and clinical studies suggest that the formulation alleviates visceral hypersensitivity, improves gastric motility, reduces low-grade duodenal inflammation, and strengthens the mucosal barrier, potentially by modulating gut microbiota and bile acid metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qi Zhi Wei Tong granules.